Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - Xinhua Pharmaceutical has successfully obtained the necessary regulatory approval for its Glucosamine Sulfate Capsules, indicating a significant step in expanding its product offerings in the pharmaceutical market [1]

Major Events - Xian Dao Intelligent (00470) has set the offer price for H-shares at HKD 45.80, with the sale volume adjustment rights fully exercised [1] - Lexin Outdoor (02720) has seen a public offering subscription rate of 3654.23 times, with a per share pricing of HKD 12.25 [1] - Aixin Yuan Zhi (00600) has achieved a public offering subscription rate of 104.82 times, with a final offer price of HKD 28.2 per share [1] - Shandong Xinhua Pharmaceutical (00719) has obtained the registration certificate for glucosamine sulfate capsules [1] - United Pharmaceutical (03933) has passed the consistency evaluation for roxithromycin capsules [1] - InnoCare Pharma (03696) has reached several drug development projects in the central nervous system and autoimmune disease fields with Kangzhi Pharmaceutical, valued at tens of millions of HKD [1] - Sunshine Insurance (06963) subsidiary plans to increase capital to Sunshine Asset Management (Hong Kong) for a total of no more than HKD 1 billion [1] - Crystal Tech Holdings (02228) has established a robotics laboratory in BASF, receiving top endorsement from the chemical industry for global technological leadership [1] - Youjia Innovation (02431) has newly secured designated projects in intelligent driving and intelligent cockpit [1] - China Resources Pharmaceutical (03320) is considering the potential sale of approximately 17.87% equity in Tianmai Biotechnology [1] Operating Performance - Hong Kong Telecom-SS (06823) reported a profit attributable to shareholders of HKD 5.286 billion for 2025 [1] - Pop Mart (09992) has achieved global sales of over 400 million units across all IP and product categories in 2025 [1] - Longfor Group (00960) reported a contract sales amount of HKD 2.45 billion in January [1] - China Jinmao (00817) recorded a signed sales amount of HKD 7.603 billion in January, an increase of 13.56% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of 1.7393 million MWh in January, a year-on-year increase of 15.25% [1] - Dekang Agriculture and Animal Husbandry (02419) sold 1.04236 million pigs in January [1] - China Oriental Education (00667) has issued a profit warning, expecting a year-on-year profit increase of 46% to 51% for the 2025 fiscal year [1] - China Nuclear International (02302) has issued a profit warning, expecting gross profit for 2025 to reach no less than approximately HKD 260 million [1] - Mingyuan Cloud (00909) has issued a profit warning, expecting net profit attributable to shareholders for 2025 to be approximately HKD 26.9 million to HKD 32.8 million, turning from loss to profit year-on-year [1]

Group 1 - The European Central Bank (ECB) President Lagarde will discuss the EU economic situation and ECB activities on February 9, with Eurozone January CPI falling to 1.7% and core CPI to 2.2%, both below the ECB's 2% medium-term target [1] - The demand for electronic storage and CPU orders is surging, with capital expenditure and orders in the computing sector maintaining high growth, indicating a sustained improvement in industry conditions [1][15] Group 2 - The Shanghai Composite Index closed at 4123.09 points, up 1.41%, while the Shenzhen Component Index rose 2.17% to 14208.44 points, and the ChiNext Index increased by 2.98% to 3332.77 points, with total trading volume reaching 2.25 trillion [2] - The retail sector is experiencing a full recovery in travel demand during the Spring Festival, with flight bookings up 10% and hotel bookings increasing by over 15% [3] Group 3 - The beverage sales during the Spring Festival are strong, with notable growth in various brands, indicating a robust demand across food and beverage categories [5] - The high-end liquor market is stable, with significant growth in premium brands, while the real estate liquor segment is expected to see a turning point mid-year [6] Group 4 - The coal supply is tightening due to reduced export quotas from Indonesia, leading to a rapid increase in coal prices, which have rebounded from a low of $38 to $49.27 [6] - The high-end consumer market is gradually recovering, with a target of double-digit growth set for 2026, particularly in luxury and soft luxury segments [7] Group 5 - The new RWA regulations in Hong Kong clarify the non-monetary nature of virtual assets and define the path for RWA, with expectations for the secondary market to open in 2026 [8][9] - The home appliance market shows significant differentiation in sales performance, with black electronics and washing machines growing, while air conditioning and refrigerators decline [10][11] Group 6 - The demand for new energy sectors is increasing, with lithium carbonate prices at 130,000, and significant growth expected in sodium battery applications and wind power orders [13] - The computing-related industry is making significant progress, with Nvidia's quartz glass substrate samples being delivered and expected improvements in production efficiency [14] Group 7 - The overseas AI capital expenditure is surging, with major companies like AWS and Google significantly increasing their capital spending, driving demand across the AI supply chain [16][17] - The optical module market is experiencing rapid growth, with demand expected to double by 2026, particularly in data centers [20]

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of glucosamine sulfate capsule, which is classified as a Class 4 chemical drug and a Class A non-prescription drug, aimed at treating primary and secondary osteoarthritis [1] Group 1 - The glucosamine sulfate capsule is available in specifications of 0.25g or 0.314g [1] - The drug has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) as a Category B product [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] - Glucosamine Sulfate Capsules are aimed at addressing a significant medical need in the treatment of osteoarthritis, a common joint disorder [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The approval of Glucosamine Sulfate Capsules marks a significant milestone for Xinhua Pharmaceutical, enhancing its product portfolio in the orthopedic treatment sector [1] - The clinical application of this product targets a growing market for osteoarthritis treatments, indicating potential revenue growth for the company [1] Industry Summary - The approval aligns with the increasing demand for effective treatments for osteoarthritis, a condition affecting a large segment of the population [1] - The pharmaceutical industry is witnessing a trend towards the development of specialized medications for chronic conditions, which may lead to increased competition and innovation in the market [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Group 1: Product Approval - The approval of Glucosamine Sulfate Capsules enhances the company's formulation product portfolio [1] - This product is classified as a Category B item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) [1] Group 2: Market Potential - The estimated sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is approximately RMB 850 million in 2024 [1] - The introduction of this product is expected to improve the company's overall competitiveness in the market [1] Group 3: Industry Considerations - The pharmaceutical sales business is subject to uncertainties influenced by industry policies and market conditions [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The company has announced the receipt of a drug registration certificate for Glucosamine Sulfate Capsules [1] - The clinical application of the product focuses on treating osteoarthritis, indicating a strategic move into the growing market for joint health [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Company Summary - The company submitted the application for the marketing authorization of Glucosamine Sulfate Capsules to the National Medical Products Administration in August 2024, and the application was accepted [1] - The drug received its registration certificate in February 2026, with the review conclusion being approval for registration [1] Industry Summary - Glucosamine Sulfate Capsules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is estimated to be approximately RMB 850 million in 2024 [1]